Michael DiGiovanna, MD/PhD
Yale Cancer Center
Co-Targeting IGF-Receptor and HER2 in Breast Cancer
Awarded $50,000
About this Project: This project studies interactions between three receptors in the body. One of these receptors may play a role in resistance to drugs that specifically target one of the other receptors, such as Herceptin and tamoxifen. In addition, one of these receptors is one member of a family of four similar receptors that work cooperatively to make cells grow. It has been discovered that a cancer’s use of the other receptors in the family may play a role in resistance to drugs that only target one of these receptors. Therefore, it may be more affective to inhibit all of the receptors rather than just the one. CT BHI has been funding this project for the past two grant funding years and continues to support its progress.